Home / Market News / $TXG
benzinga Corporate Catalyst Impact 55/100 ● positive

Canaccord Genuity Maintains Buy on 10x Genomics, Raises Price Target to $100

Oct 12, 2026, 5:07 PM UTC · Primary ticker $TXG

Canaccord Genuity analyst Kyle Mikson reiterated a 'Buy' rating for 10x Genomics (TXG) and significantly increased its price target from $60 to $100. This analyst action suggests a more optimistic outlook on the company's future performance and valuation.

Canaccord Genuity's analyst Kyle Mikson has maintained a 'Buy' rating on 10x Genomics (TXG) and raised the price target from $60 to $100. This is a significant upward revision, indicating increased confidence in the company's growth prospects and fundamental value. For traders, this could signal short-term positive momentum as the market reacts to the analyst's upgraded outlook, potentially leading to increased buying interest. Long-term implications depend on whether the company's performance can justify this higher valuation, but it presents an opportunity for those bullish on TXG's technology and market position. The primary risk is that the market may not fully agree with the analyst's assessment, or that future company performance could fall short of expectations.

$TXG positive Analyst price target increase
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.